Machine Learning Predictive Model to Guide Treatment Allocation for Recurrent Hepatocellular Carcinoma After Surgery

医学 索拉非尼 肝细胞癌 队列 肝硬化 肝切除术 接收机工作特性 内科学 外科 回顾性队列研究 切除术
作者
Simone Famularo,Matteo Donadon,Federica Cipriani,Federico Fazio,Francesco Ardito,Maurizio Iaria,Pasquale Perri,Simone Conci,Tommaso Dominioni,Quirino Lai,Giuliano La Barba,Stefan Patauner,Sarah Molfino,Paola Germani,Giuseppe Zimmitti,Enrico Pinotti,Matteo Zanello,Luca A. M. Fumagalli,Cecilia Ferrari,Maurizio Romano
出处
期刊:JAMA Surgery [American Medical Association]
卷期号:158 (2): 192-192 被引量:40
标识
DOI:10.1001/jamasurg.2022.6697
摘要

Importance: Clear indications on how to select retreatments for recurrent hepatocellular carcinoma (HCC) are still lacking. Objective: To create a machine learning predictive model of survival after HCC recurrence to allocate patients to their best potential treatment. Design, Setting, and Participants: Real-life data were obtained from an Italian registry of hepatocellular carcinoma between January 2008 and December 2019 after a median (IQR) follow-up of 27 (12-51) months. External validation was made on data derived by another Italian cohort and a Japanese cohort. Patients who experienced a recurrent HCC after a first surgical approach were included. Patients were profiled, and factors predicting survival after recurrence under different treatments that acted also as treatment effect modifiers were assessed. The model was then fitted individually to identify the best potential treatment. Analysis took place between January and April 2021. Exposures: Patients were enrolled if treated by reoperative hepatectomy or thermoablation, chemoembolization, or sorafenib. Main Outcomes and Measures: Survival after recurrence was the end point. Results: A total of 701 patients with recurrent HCC were enrolled (mean [SD] age, 71 [9] years; 151 [21.5%] female). Of those, 293 patients (41.8%) received reoperative hepatectomy or thermoablation, 188 (26.8%) received sorafenib, and 220 (31.4%) received chemoembolization. Treatment, age, cirrhosis, number, size, and lobar localization of the recurrent nodules, extrahepatic spread, and time to recurrence were all treatment effect modifiers and survival after recurrence predictors. The area under the receiver operating characteristic curve of the predictive model was 78.5% (95% CI, 71.7%-85.3%) at 5 years after recurrence. According to the model, 611 patients (87.2%) would have benefited from reoperative hepatectomy or thermoablation, 37 (5.2%) from sorafenib, and 53 (7.6%) from chemoembolization in terms of potential survival after recurrence. Compared with patients for which the best potential treatment was reoperative hepatectomy or thermoablation, sorafenib and chemoembolization would be the best potential treatment for older patients (median [IQR] age, 78.5 [75.2-83.4] years, 77.02 [73.89-80.46] years, and 71.59 [64.76-76.06] years for sorafenib, chemoembolization, and reoperative hepatectomy or thermoablation, respectively), with a lower median (IQR) number of multiple recurrent nodules (1.00 [1.00-2.00] for sorafenib, 1.00 [1.00-2.00] for chemoembolization, and 2.00 [1.00-3.00] for reoperative hepatectomy or thermoablation). Extrahepatic recurrence was observed in 43.2% (n = 16) for sorafenib as the best potential treatment vs 14.6% (n = 89) for reoperative hepatectomy or thermoablation as the best potential treatment and 0% for chemoembolization as the best potential treatment. Those profiles were used to constitute a patient-tailored algorithm for the best potential treatment allocation. Conclusions and Relevance: The herein presented algorithm should help in allocating patients with recurrent HCC to the best potential treatment according to their specific characteristics in a treatment hierarchy fashion.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
燕晓啸完成签到 ,获得积分0
2秒前
2秒前
脑洞疼的应助被Laney采纳,获得10
3秒前
hyn完成签到 ,获得积分10
3秒前
科研通AI65的应助被龍鷹采纳,获得10
3秒前
涂鹏辉发布了新的文献求助10
3秒前
JohnCZz完成签到,获得积分10
4秒前
香蕉觅云的应助被xie采纳,获得10
4秒前
Jessie完成签到 ,获得积分10
4秒前
beplayer1完成签到,获得积分0
6秒前
6秒前
6秒前
7秒前
枯木完成签到 ,获得积分10
7秒前
ding的应助被风中的宛白采纳,获得10
7秒前
SciGPT的应助被懵懂的灭男采纳,获得10
7秒前
8秒前
8秒前
8秒前
YDTian完成签到 ,获得积分10
8秒前
8秒前
9秒前
和谐如风发布了新的文献求助10
9秒前
shunshun51213完成签到,获得积分10
9秒前
9秒前
9秒前
苏邑发布了新的文献求助10
9秒前
9秒前
10秒前
10秒前
10秒前
10秒前
dan1029发布了新的文献求助10
10秒前
10秒前
10秒前
dan1029发布了新的文献求助10
10秒前
10秒前
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181408
求助须知:如何正确求助?哪些是违规求助? 9571330
关于积分的说明 21817615
捐赠科研通 7777856
什么是DOI,文献DOI怎么找? 3433479
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479527